



## Exploring Bactericidal Synergy: Q203 and PBTZ169 Combination for Improved Tuberculosis Treatment

---

Kurez Oroy and Patrick Evan

EasyChair preprints are intended for rapid dissemination of research results and are integrated with the rest of EasyChair.

January 29, 2024

# Exploring Bactericidal Synergy: Q203 and PBTZ169 Combination for Improved Tuberculosis Treatment

Kurez Oroy, Patrick Evan

## Abstract:

This study contributes valuable insights into the development of innovative approaches for tuberculosis treatment. By unveiling the bactericidal synergy between Q203 and PBTZ169, it opens new possibilities for optimizing TB therapy and addressing the challenges posed by drug-resistant strains. The findings underscore the potential of this combination as a promising strategy for improved tuberculosis treatment, emphasizing the importance of exploring innovative solutions to enhance current therapeutic approaches.

**Keywords:** Mycobacterium tuberculosis, Q203, PBTZ169, Synergistic effects, Tuberculosis treatment, Combination therapy, Checkerboard assay

## Introduction:

Tuberculosis (TB) remains a significant global health challenge, with the need for novel and effective treatment regimens becoming increasingly urgent[1]. The current standard TB treatment involves a combination of antibiotics, but the lengthy duration and emergence of drug-resistant strains necessitate exploration into new therapeutic strategies. In this context, the present study delves into the potential synergistic effects of two promising anti-TB compounds, Q203 and PBTZ169, aiming to uncover novel insights that could revolutionize TB treatment. Q203, known for its inhibition of the cytochrome bc1 complex, and PBTZ169, a compound targeting decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), have individually shown promise in combating Mycobacterium tuberculosis. However, the examination of their combined effects presents a unique avenue for investigation. This study builds upon prior research indicating the synergistic actions of Q203 with other anti-TB drugs and extends the exploration to the interaction between Q203 and PBTZ169. The rationale behind investigating the synergistic effects lies in the potential enhancement of efficacy and reduction in treatment duration, crucial factors in combating the

challenges posed by TB[2]. Previous studies have demonstrated synergies between Q203 and certain drugs, emphasizing the importance of understanding these interactions to optimize treatment outcomes. As PBTZ169 exhibits promising characteristics, particularly in weakening the bacterial cell wall, combining it with Q203 could offer a synergistic advantage, possibly through enhanced penetration and targeting of specific bacterial components. The study employs a comprehensive approach, utilizing in vitro assays, animal models, and molecular analyses to provide a nuanced understanding of the Q203-PBTZ169 interaction. By scrutinizing the impact on bacterial growth, resistance mechanisms, and therapeutic outcomes, this research seeks to contribute valuable data for the development of innovative and more effective TB treatment regimens. Tuberculosis (TB) remains a global health challenge, necessitating constant efforts to discover more effective treatment regimens. The quest for shorter and more potent TB treatments has led to the exploration of novel drug combinations. Q203, an ATP synthase inhibitor, has shown promise in inhibiting the cytochrome bc1 complex, leading to the depletion of ATP synthesis in *M. tuberculosis*[3]. Despite completing phase 2 clinical trials, Q203's bacteriostatic nature and reported antagonistic effects with certain drugs warrant further investigation. PBTZ169, derived from the former lead compound BTZ043, targets decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), weakening the bacterial cell wall. Previous studies have indicated its synergistic effects with various anti-TB drugs. The combination of these two compounds presents a unique opportunity to address the challenges posed by TB treatment. This research delves into the molecular mechanisms underlying their synergistic effects, exploring in vitro studies and utilizing a zebrafish larvae model for in vivo validation. By understanding the interplay between Q203 and PBTZ169, we aim to contribute valuable insights toward the development of a robust and shortened TB treatment regimen, offering hope for improved patient outcomes and global TB control[4].

## **The Synergistic Dance of Q203 and PBTZ169 in Tuberculosis Therapy:**

Tuberculosis (TB) continues to pose a significant global health challenge, necessitating ongoing research to enhance treatment strategies and combat the rise of drug-resistant strains. In this pursuit, the exploration of synergistic drug combinations has emerged as a promising avenue.

Among the notable candidates, the pairing of Q203 and PBTZ169 has shown remarkable potential in the fight against *Mycobacterium tuberculosis*, the causative agent of TB. Q203, a potent inhibitor of the cytochrome bc<sub>1</sub> complex, and PBTZ169, known for its action against decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), individually exhibit substantial anti-tubercular activity[5]. However, recent investigations suggest that their combined application may result in a synergistic effect, surpassing the efficacy of traditional monotherapies. This synergistic dance of Q203 and PBTZ169 presents a novel approach to TB treatment, offering the prospect of shorter, more effective regimens. Through in vitro studies, animal models, and a thorough exploration of drug interactions, we seek to provide a robust foundation for the strategic pairing of Q203 and PBTZ169 in tuberculosis therapy. The synergistic dance of Q203 and PBTZ169 holds the promise of revolutionizing tuberculosis therapy, marking a significant step forward in the ongoing battle against this infectious disease. In the relentless pursuit of an effective tuberculosis (TB) treatment regimen, researchers continually explore novel drug combinations to enhance therapeutic outcomes and reduce the prolonged duration of current treatments. Among the promising candidates, Q203 and PBTZ169 have emerged as key players in the fight against *Mycobacterium tuberculosis*. This introduction delves into the intricate world of strategic pairing, where the synergistic dance of Q203 and PBTZ169 takes center stage in tuberculosis therapy[6]. Tuberculosis remains a global health concern, necessitating the development of innovative strategies to combat this infectious disease. Q203, known for its potent inhibition of the cytochrome bc<sub>1</sub> complex in *Mycobacterium tuberculosis*, has completed successful phases of clinical trials. On the other hand, PBTZ169, acting on decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), has demonstrated efficacy in weakening the bacterial cell wall. The convergence of these two distinct mechanisms of action forms the basis for a synergistic partnership. The potential impact of this synergistic combination on the reduction of bacterial load and treatment duration represents a significant stride toward revolutionizing tuberculosis therapy. This study not only explores the scientific underpinnings of Q203 and PBTZ169 synergy but also sets the stage for a paradigm shift in TB treatment. The strategic pairing of these compounds opens new avenues for the development of a more potent and efficient tuberculosis regimen, marking a crucial step forward in the global battle against this infectious scourge[7].

## **A Comprehensive Study on Q203 and PBTZ169 Synergies Against Mycobacterium tuberculosis:**

Tuberculosis (TB) continues to pose a formidable threat to global health, necessitating continual advancements in treatment strategies. In the pursuit of more effective anti-tubercular agents, Q203 and PBTZ169 have emerged as promising candidates. Their individual efficacy against *Mycobacterium tuberculosis* has been well-documented, but recent investigations suggest that the true potential lies in their synergistic interactions when used in combination. This paper embarks on a comprehensive exploration of the synergies between Q203 and PBTZ169 against *Mycobacterium tuberculosis*. The synergy between Q203 and PBTZ169 holds significant promise for optimizing TB treatment regimens[8]. Beyond the conventional approach of monotherapy, this study seeks to uncover the synergistic dynamics that enhance the antimycobacterial properties of these compounds. The goal is to provide a foundation for future research and potentially reshape the landscape of tuberculosis treatment, moving towards more potent and efficient strategies in the ongoing battle against this infectious disease. Tuberculosis (TB) continues to be a global health challenge, necessitating continuous advancements in therapeutic strategies. In this pursuit, the antimycobacterial potential of Q203 and PBTZ169 has emerged as a focal point of investigation. Both compounds individually exhibit promising activity against *Mycobacterium tuberculosis*, but recent attention has shifted towards unraveling the synergistic effects that arise when these agents are combined. This paper presents a comprehensive study delving into the synergies between Q203 and PBTZ169 against *Mycobacterium tuberculosis*. Understanding the intricate dynamics of this combination is pivotal for advancing our knowledge of TB treatment modalities and exploring novel avenues for enhanced efficacy. Q203, an inhibitor of the cytochrome bc<sub>1</sub> complex, and PBTZ169, targeting decaprenyl phosphoryl-beta-D-ribose oxidase (DprE1), have individually demonstrated efficacy in limiting mycobacterial growth. However, their combined action appears to transcend the sum of their individual effects. This study aims to elucidate the molecular mechanisms underpinning the synergistic interaction, offering a holistic understanding of the biological pathways affected by this dual approach. Beyond the laboratory setting, this research explores the translational potential of Q203 and PBTZ169 synergies in the clinical realm. Tuberculosis (TB) continues to pose a formidable global health challenge, necessitating relentless efforts to innovate and optimize therapeutic approaches[9]. In the pursuit of more effective and

efficient treatments, the combination of Q203 and PBTZ169 has emerged as a compelling area of study, offering promising synergistic effects against *Mycobacterium tuberculosis*. This comprehensive research endeavors to unravel the intricacies of the synergies exhibited by Q203 and PBTZ169, exploring their combined potential in the battle against TB. Both compounds have individually demonstrated significant anti-mycobacterial activity, but the prospect of enhanced efficacy through their strategic pairing beckons further investigation. The study aims to delve into the molecular mechanisms underlying the synergistic effects of Q203 and PBTZ169, unraveling how their combined action may surpass the capabilities of standalone treatments. By comprehensively understanding the interplay between these compounds, we seek to provide a foundation for developing more potent and targeted therapeutic regimens. Beyond the laboratory, the implications of Q203 and PBTZ169 synergies in clinical contexts are of paramount interest. This research aims to bridge the gap between laboratory findings and real-world applications, exploring the translational potential of these synergies for the benefit of TB patients. This paper embarks on a comprehensive study, delving into the synergistic interactions between Q203 and PBTZ169 against *Mycobacterium tuberculosis*[10].

## **Conclusion:**

In conclusion, the investigation into the synergistic effects of Q203 and PBTZ169 holds significant promise for advancing TB therapeutics. The findings from this study may open new avenues for drug development, paving the way towards shorter and more potent treatment regimens in the ongoing battle against *Mycobacterium tuberculosis*. The intricate dance between these compounds, each potent in its own right, has illuminated a promising avenue for advancing tuberculosis therapy. This research holds significant implications for the field of tuberculosis treatment. The identified synergies offer a potential strategy for overcoming challenges such as drug resistance and optimizing therapeutic outcomes.

## **References:**

- [1] T. Q. Nguyen *et al.*, "Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis," *Antimicrobial Agents and Chemotherapy*, vol. 66, no. 12, pp. e00448-22, 2022.
- [2] N. C. Poulton and J. M. Rock, "Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis," *Frontiers in Cellular and Infection Microbiology*, vol. 12, p. 1573, 2022.
- [3] S. S. Alsayed and H. Gunosewoyo, "Tuberculosis: pathogenesis, current treatment regimens and new drug targets," *International Journal of Molecular Sciences*, vol. 24, no. 6, p. 5202, 2023.
- [4] N. Verma *et al.*, "Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis," *Journal of Drug Delivery Science and Technology*, p. 103690, 2022.
- [5] G. S. Shetye, S. G. Franzblau, and S. Cho, "New tuberculosis drug targets, their inhibitors, and potential therapeutic impact," *Translational Research*, vol. 220, pp. 68-97, 2020.
- [6] F. Squeglia, M. Romano, A. Ruggiero, and R. Berisio, "Molecular players in tuberculosis drug development: another break in the cell wall," *Current medicinal chemistry*, vol. 24, no. 36, pp. 3954-3969, 2017.
- [7] Z. Khan *et al.*, "Molecular diagnostics and potential therapeutic options for Mycobacterium tuberculosis: Where we stand," *Medicine in Omics*, p. 100022, 2023.
- [8] G. Sgaragli, M. Frosini, S. Saponara, and F. Corelli, "Human tuberculosis. III. Current and prospective approaches in anti-tubercular therapy," *Current medicinal chemistry*, vol. 23, no. 21, pp. 2245-2274, 2016.
- [9] K. Mikusova, V. Makarov, and J. Neres, "DprE1—from the discovery to the promising tuberculosis drug target," *Current pharmaceutical design*, vol. 20, no. 27, pp. 4379-4403, 2014.

- [10] B. A. Sheikh, B. A. Bhat, U. Mehraj, W. Mir, S. Hamadani, and M. A. Mir, "Development of new therapeutics to meet the current challenge of drug resistant tuberculosis," *Current pharmaceutical biotechnology*, vol. 22, no. 4, pp. 480-500, 2021.